**BACKGROUND:** Onabotulinumtoxin A (BOTOX®) is an FDA-approved treatment for chronic migraine headaches that involves on-label, high-dose administration across 31 anatomic sites. Anatomically-specific peripheral nerve trigger sites have been identified that contribute to migraine headache pathogenesis and are amenable to both BOTOX® injection and surgical decompression. These sites do not always correlate with the on-label FDA-approved injection pattern, but represent a more targeted approach. The efficacy of targeted peripheral nerve trigger site BOTOX® injection as an independent long-term therapeutic option has not been investigated.

**METHODS:** A retrospective review was completed for 223 patients with migraine headaches. Sixty-six patients elected to proceed with diagnostic BOTOX® injections. Of these, 24 continued long-term therapeutic BOTOX® injections while 42 matriculated to surgery. Outcomes were tracked.

**RESULTS:** Therapeutic long-term targeted trigger site-directed BOTOX® injection resulted in significant improvement in migraine headache index (MHI) (53.5+/-83.0, p\<0.006), headache days/month (9.2+/-12.7, p\<0.0009) and migraine severity (2.6+/-2.5, p\<0.00008) versus baseline. MHI improved from the initiation of diagnostic injections to the establishment of steady-state injections (p\<0.002), and further improved over time (p\<0.05, mean follow-up 615 days) with no desensitization observed. Decompressive surgery resulted in significant improvement in MHI (100.8+/-109.7, p\<0.0000005), headache days/month (10.8+/-12.7, p\<0.000002), migraine severity (3.0 +/- 3.8, p\<0.00001), and migraine duration in hours (16.8+/-21.6, p\<0.0007). MHI improvement with surgery was better than long-term BOTOX® injections (p\<0.05).

**CONCLUSIONS:** Though inferior to surgical decompression, targeted peripheral nerve trigger site-directed BOTOX® injection is an effective primary therapy for migraine headache representing a possible alternative to non-directed BOTOX® injection with decreased dosage requirements and the potential for decreased cost.
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